Adimab

About Adimab

Adimab is the most successful antibody discovery and engineering company in the industry and the partner of choice for biopharma. Since 2007, we’ve collaborated with global pharma, cutting-edge biotech, and leading academic institutions to generate high-quality therapeutic leads across a wide range of targets and formats. Our proprietary yeast-based platform enables end-to-end discovery, optimization, and developability assessment, delivering fully human IgGs, HCAbs, multispecifics, and other protein-based modalities, including TCRs, with speed, precision, and reliability. We have worked on 650+ discovery campaigns and generated 90+ clinical programs created with more than 140 partners. With no internal pipeline, every program reflects our full commitment to our partners’ success.